Rituximab in Patients With Phospholipase A2 Receptor–Associated Membranous Nephropathy and Severe CKD
INTRODUCTION: Patients with phospholipase A2 receptor (PLA2R)–associated membranous nephropathy and stage 4 or 5 chronic kidney disease are at high risk of end-stage kidney disease. In recent years, rituximab (RTX) emerged as a safe and efficient treatment for patients with PLA2R-associated membrano...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7056852/ https://www.ncbi.nlm.nih.gov/pubmed/32154454 http://dx.doi.org/10.1016/j.ekir.2019.12.006 |